Interleukin-35 expression is associated with colon cancer progression

Jian Zhang; Tao Mao; Shuyun Wang; Dongsheng Wang; Zhaojian Niu; Zhenqing Sun; Jianli Zhang

doi:10.18632/oncotarget.17751

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Expression of Concern

This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.

Interleukin-35 expression is associated with colon cancer progression

Jian Zhang _, Tao Mao, Shuyun Wang, Dongsheng Wang, Zhaojian Niu, Zhenqing Sun and Jianli Zhang

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:71563-71573. https://doi.org/10.18632/oncotarget.17751

Metrics: PDF 2459 views | HTML 2982 views | ?

Abstract

Jian Zhang1, Tao Mao1, Shuyun Wang1, Dongsheng Wang1, Zhaojian Niu1, Zhenqing Sun1 and Jianli Zhang1

1Department of General Surgery, The Affiliated Hospital of Qingdao University, Qingdao, P.R. China

Correspondence to:

Jian Zhang, email: [email protected]

Jianli Zhang, email: [email protected]

Keywords: interleukin-35, colon cancer, β-catenin, IL-35

Received: April 04, 2017 Accepted: April 27, 2017 Published: May 10, 2017

ABSTRACT

Colon cancer development is closely related to inflammation. Thus, we conducted the present investigation to study the effects of IL-35 (Interleukin 35), a newly identified anti-inflammatory factor, on colon cancer development. We first evaluated the IL-35 expression in 186 pairs of colon cancer samples and paired adjacent normal tissues by qPCR, ELISA (Enzyme-linked immunoassay) and tissue microarrays. Then the role of IL-35 on patient survival rates, colon cancer progression and their sensitivity to chemotherapy drugs were assessed. IL-35 was barely expressed in the colon cancer tissue but highly expressed in the adjacent normal tissue. The down-regulation of IL-35 was significantly associated with the AJCC (American Joint Committee on Cancer) stage, nodal involvement, invasion depth, distant metastasis, differentiation and it was also shown to be an independent prognostic indicator of both disease-free and overall survivals for colon cancer patients. Overexpression of IL-35 in colon cancer cell suppressed cell migration, invasion, proliferation, colony formation and cancer stem cells through suppressing β-catenin. IL-35 inhibited colon tumor formation in the mice model and sensitize the cancer cell to chemotherapy drugs. Our results showed that IL-35 shows an inhibitory effect in colon cancer development and is a novel prognostic indicator. Therefore, IL-35 might be a potential therapeutic target.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17751

Publication Alerts

Research Papers:

Interleukin-35 expression is associated with colon cancer progression

Abstract